C(F)(F)F)NS(=O)(=O)C1=CC(F)=C2CNCCC2=C1)N1CCCC1](https://cdn.shopify.com/s/files/1/0389/1897/9723/products/M9557_1621560427.gif?v=1621560429)
Pay in 4 interest-free payments of $20.00 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Smiles: O=C([C@@H](CC1C=C(C=CC=1)C(F)(F)F)NS(=O)(=O)C1=CC(F)=C2CNCCC2=C1)N1CCCC1
Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors
7-disulfonamide
Widdison WC et al
Mianserin (2 mg/kg s
Ivacaftor hydrate 5109 HCl Smiles: O=C([C@@H](CC1C=C(C=CC=1)C(F)(F)F)NS(=O)(=O)C1=CC(F)=C2CNCCC2=C1)N1CCCC1VX 770, is a drug used to treat cystic fibrosis in people with certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, who account for 45% cases of cystic fibrosis, and is included in a combination drug, lumacaftor ivacaftor, which is used to treat people with cystic fibrosis who have the F508del mutation in CFTR. Ivacaftor is a "potentiator" of CFTR, meaning it increases the probability that the defective channel
US$ 1029.99
US$ 137.75
US$ 21.98
US$ 27.98
US$ 870.98
US$ 15.98
US$ 124.97
US$ 771.98
US$ 33.98